Market Closed -
Nasdaq
04:30:01 2024-03-28 pm EDT
5-day change
1st Jan Change
23.73
USD
-0.54%
-0.79%
-1.08%
Sales 2024 *
1.9B
Sales 2025 *
2.07B
Capitalization
7.23B
Net income 2024 *
377M
Net income 2025 *
446M
EV / Sales 2024 *
3.21
x
Net cash position
2024
*
1.12B
Net cash position
2025
*
1.65B
EV / Sales 2025 *
2.69
x P/E ratio 2024 *
19.2
x
P/E ratio 2025 *
16.1
x
Employees
1,310
Yield 2024 *
-
Yield 2025 *
-
Free-Float
97.66%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Transcript : Exelixis, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:45 AM
Mar. 13
Transcript : Exelixis, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 09:20 AM
Mar. 12
Transcript : Exelixis, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM
Mar. 05
Exelixis Insider Bought Shares Worth $3,932,734, According to a Recent SEC Filing
Feb. 22
MT
Transcript : Exelixis, Inc. Presents at Oppenheimer 34th Annual Healthcare Life Sciences Conference, Feb-13-2024 12:40 PM
Feb. 13
Transcript : Exelixis, Inc. Presents at Guggenheim Healthcare Talks| 6th Annual Biotechnology Conference, Feb-08-2024 09:00 AM
Feb. 08
RBC Raises Price Target on Exelixis to $28 From $26, Keeps Outperform Rating
Feb. 07
MT
Exelixis Swings to Earnings in Fiscal Q4 as Sales Increase; 2024 Revenue Guidance Set
Feb. 06
MT
Transcript : Exelixis, Inc., Q4 2023 Earnings Call, Feb 06, 2024
Feb. 06
Exelixis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 06
CI
Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024
Feb. 06
CI
Earnings Flash (EXEL) EXELIXIS Reports Q4 Revenue $480M, vs. Street Est of $477.9M
Feb. 06
MT
Earnings Flash (EXEL) EXELIXIS Posts Q4 EPS $0.33, vs. Street Est of $0.31
Feb. 06
MT
Exelixis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Feb. 06
CI
Barclays Adjusts Price Target on Exelixis to $25 From $24, Keeps Overweight Rating
Jan. 30
MT
More news
Ipsen s'apprête à présenter de nouvelles données positives sur le Cabometyx
Jan. 23
En Direct des Marchés : TotalEnergies, Unibail, Saint-Gobain, Ipsen, Abivax, Amazon, Ryanair...
23-08-21
Les valeurs à suivre aujourd'hui à la Bourse de Paris - Lundi 21 août 2023
23-08-21
Ipsen : Exelixis et Ipsen annoncent les résultats positifs de l’'essai pivot de Phase III CONTACT-02
23-08-21
EN DIRECTO DESDE LOS MERCADOS: Aena, TotalEnergies, FedEx, Volkswagen, Adobe, Ipsen, Abivax, Amazon, Ryanair...
23-08-21
More news 1 day -0.54%
1 week -0.79%
Current month +8.36%
1 month +8.31%
3 months -1.66%
6 months +5.98%
Current year -1.08%
More quotes
Managers
Title Age Since
Chief Executive Officer
63
00-01-31
Director of Finance/CFO
56
15-07-14
Chief Tech/Sci/R&D Officer
57
23-08-22
Members of the board
Title Age Since
Director/Board Member
68
04-12-31
Director/Board Member
68
04-01-31
Director/Board Member
79
04-07-31
More insiders
Date
Price
Change
Volume
24-03-28
23.73
-0.54%
2,953,471
24-03-27
23.86
+1.06%
1,615,533
24-03-26
23.61
-0.38%
1,879,807
24-03-25
23.7
-0.34%
2,257,961
24-03-22
23.78
-0.59%
1,933,633
Delayed Quote
Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotes
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
More about the company
Last Close Price
23.73
USD
Average target price
26.63
USD
Spread / Average Target
+12.22%
Consensus
1st Jan change
Capi.
-1.08% 7.23B +2.73% 108B +9.59% 104B +6.58% 23.66B -12.59% 22.1B -3.29% 19.71B -35.36% 18.2B -13.29% 16.19B +4.68% 13.72B +34.25% 12.22B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1